Glaxosmithkline plc, of London, is collaborating with the ALS Association, Harvard Stem Cell Institute and Massachusetts General Hospital Neurological Clinical Research Institute on a new amyotrophic lateral sclerosis (ALS) trial to include testing using stem cells from patients.